Understanding the mechanism of action for intravenous immunoglobulin (IVIG) therapy in spinal cord injury

点击翻译按钮获取中文摘要

Traumatic spinal cord injury is an important and costly cause of disability in Australia. The body's immune system plays a key role in the recovery from such injuries, but treatments to effectively target post-traumatic inflammation are lacking. This grant will test a promising new therapy, intravenous immunoglobulin (IVIG), and in particular uncover what cells and molecules are targeted by it so that we can better treat individuals affected by these devastating injuries.